Speaker illustration

Professor Erik Stroes

Academic Medical Center of Amsterdam, Amsterdam (Netherlands (The))

Member of:

European Society of Cardiology

Prof Stroes has been involved in the cardiovascular research field for 25 years with a strong focus on lipids, inflammation and imaging. He has co-authored more than 490 peer-reviewed papers on translational and clinical research. He has contributed to multiple landmark trials in cardiovascular prevention. His group has been involved in early drug research in the field of inflammation and lipids in the last 20 years.

Lp(a): from causality to therapy

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session type: Satellite Symposium

Thumbnail

Lower for longer: reframing the clinical goal for LDL-C. The lower the better is no longer enough

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session type: Satellite Symposium

Thumbnail

Add on to take back control: Combining lipid lowering therapies for the management of high and very high risk patients

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipids

Session type: Satellite Symposium

Thumbnail

Lp(a): From CV risk marker to therapeutic target

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Lp(a), a new lipid frontier in CV risk management & target for therapy

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Lipids

Session type: Industry Q&A session

Thumbnail

2016 Dyslipidaemias Guidelines in The Netherlands

Event: ESC CONGRESS 2016

Topic: Epidemiology, lipids

Session type: Guidelines in Practice

Thumbnail

PCSK9i: translating data into daily practice

Event: ESC CONGRESS 2016

Topic: Lipids

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

PCSK9i: translating data into daily practice.

Event: ESC CONGRESS 2016

Topic: Lipids

Session type: Satellite Symposium

Thumbnail

PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients

Event: ESC CONGRESS 2015

Topic: Lipids

Session type: Satellite Symposium

Thumbnail

PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients

Event: ESC CONGRESS 2015

Topic: Lipids

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

This platform is supported by

logo Novo Nordisk